Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IsoPlexis CorpISO · Entity 115290 | Director | June 16, 2022 | June 21, 2022 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | Director · President & CEO | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IsoPlexis Corp
Report date June 16, 2022 · Filed June 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2032-06-10 | Direct | 89,047 |
Reported balance
After 2022-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-16 · Grant · Acquired 89,047 · Balance 89,047 F1: Option vests in full on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the next annual shareholders meeting |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests in full on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the next annual shareholders meeting
STANDARD BIOTOOLS INC.
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,137,704 |
Reported balance
After 2026-08-20 transaction · row 1
1 source rowRow 1 · 2026-08-20 · Tax withholding · Disposed 97,627 · Balance 6,137,704 F1: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024, March 21, 2025 and March 20, 2026, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024, March 24, 2025 and April 8, 2026 respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024, March 21, 2025 and March 20, 2026, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024, March 24, 2025 and April 8, 2026 respectively.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 24, 2026 21:04 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 97,627 | $0.67 | $65,605.34 |
DisclosureSEC source: 0001193125-26-363758 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,137,704 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024, March 21, 2025 and March 20, 2026, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024, March 24, 2025 and April 8, 2026 respectively. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:01 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 362,625 | $0.87 | $314,758.50 |
DisclosureSEC source: 0001193125-26-333225 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,235,331 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on August 1, 2025, which grant was originally reported on a Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2025. Read SEC document |
| May 20, 2026 Filed May 22, 2026 21:17 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 97,626 | $1.00 | $97,626.00 |
DisclosureSEC source: 0001193125-26-237181 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,597,956 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024, March 21, 2025 and March 20, 2026, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024, March 24, 2025 and April 8, 2026, respectively. Read SEC document |
| April 06, 2026 Filed Apr 9, 2026 01:55 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 196,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-148615 · ownership.xml · derivative · entry 5 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 196,513 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023. F5 · derivative.expiration_date: On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023. Read SEC document |
| April 06, 2026 Filed Apr 9, 2026 01:55 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 95,014 | $0.91 | $86,272.71 |
DisclosureSEC source: 0001193125-26-148615 · ownership.xml · nonDerivative · entry 3 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,695,582 F2 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of RSUs granted to the reporting person on April 4, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 6, 2022. Read SEC document |
| April 06, 2026 Filed Apr 9, 2026 01:55 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Exercise / conversionCommon Stock | 196,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-148615 · ownership.xml · nonDerivative · entry 2 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,790,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2026 Filed Apr 9, 2026 01:55 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to buy) · Derivative | 2,345,340 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001193125-26-148615 · ownership.xml · derivative · entry 4 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,345,340 Underlying: Common Stock · 2,345,340 shares Expires 2036-03-20 F3 · derivative.exercise_date: The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| March 20, 2026 Filed Apr 9, 2026 01:55 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 1,042,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-148615 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,594,083 F1 · shares: Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 22:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 66,127 | $1.15 | $76,046.05 |
DisclosureSEC source: 0001193125-26-067641 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,551,710 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024 and March 24, 2025, respectively. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:05 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 63,529 | $1.28 | $81,317.12 |
DisclosureSEC source: 0001193125-25-293843 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,617,837 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024 and March 24, 2025, respectively. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 21:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 54,919 | $1.27 | $69,747.13 |
DisclosureSEC source: 0000950170-25-111052 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,681,366 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024 and March 24, 2025, respectively. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:23 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 3,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-103296 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,736,285 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 25% of the RSUs on August 1, 2026, with the remaining 75% of the RSUs vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. F2 · balance_after: Includes 5,000 shares previously acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 28, 2025 Filed May 30, 2025 21:48 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 9,906 | $1.09 | $10,797.54 |
DisclosureSEC source: 0000950170-25-079886 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,731,285 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 24, 2025. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:44 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | SaleCommon Stock | 5,473 | $0.94 | $5,150.09 |
DisclosureSEC source: 0000950170-25-078457 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,741,191 F1 · shares: The shares were sold to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission ("SEC") on March 24, 2025. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $0.92 to $0.9748 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 22, 2025 Filed May 28, 2025 00:28 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | SaleCommon Stock | 5,116 | $1.00 | $5,126.23 |
DisclosureSEC source: 0000950170-25-078043 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,746,664 F1 · shares: The shares were sold to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission ("SEC") on March 24, 2025. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $0.9403 to $1.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 21, 2025 Filed May 23, 2025 00:03 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | SaleCommon Stock | 4,719 | $1.03 | $4,860.57 |
DisclosureSEC source: 0000950170-25-076591 · ownership.xml · nonDerivative · entry 2 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,751,780 F2 · shares: The shares were sold to satisfy the tax withholding obligations that arose upon the vesting of RSUs granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the SEC on March 24, 2025. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $1.015 to $1.05 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 20, 2025 Filed May 23, 2025 00:03 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 18,343 | $1.05 | $19,260.15 |
DisclosureSEC source: 0000950170-25-076591 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,756,499 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units ("RSUs") granted to the reporting person on May 20, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission ("SEC") on May 21, 2024. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 20:04 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 196,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-052047 · ownership.xml · derivative · entry 3 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,513 Underlying: Common Stock · 196,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023. F3 · derivative.expiration_date: On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 20:04 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 57,676 | $1.07 | $61,713.32 |
DisclosureSEC source: 0000950170-25-052047 · ownership.xml · nonDerivative · entry 2 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,774,842 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units ("RSUs") granted to the reporting person on April 4, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 6, 2022. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 20:04 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Exercise / conversionCommon Stock | 196,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-052047 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,832,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 22:31 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to buy) · Derivative | 1,782,500 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0000950170-25-044008 · ownership.xml · derivative · entry 2 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,782,500 Underlying: Common Stock · 1,782,500 shares Expires 2035-03-21 F2 · derivative.exercise_date: The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2025, with the remaining shares vesting in equally quarterly installments, thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 22:31 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 1,188,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-044008 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,636,006 F1 · shares: Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2025 and the remaining RSUs vesting in equally quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:30 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 31,031 | $1.39 | $43,133.09 |
DisclosureSEC source: 0000950170-25-025806 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,447,673 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 21, 2024. F2 · balance_after: Includes 5,000 shares of common stock acquired by the reporting person on May 31, 2024 under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 01:55 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 28,795 | $1.51 | $43,480.45 |
DisclosureSEC source: 0000950170-24-129877 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,473,704 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 21, 2024. Read SEC document |
| August 20, 2024 Filed Sep 5, 2024 21:59 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 29,093 | $1.91 | $55,567.63 |
DisclosureSEC source: 0000950170-24-104132 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,502,499 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 21, 2024. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:37 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 2,250,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0000950170-24-063097 · ownership.xml · derivative · entry 2 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250,000 Underlying: Common Stock · 2,250,000 shares Expires 2034-05-20 F2 · derivative.exercise_date: The Option becomes exercisable as to 1/16th of the underlying shares on August 20, 2024, with the remaining shares vesting in equal quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:37 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-063097 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,531,592 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 1/16th of the RSUs on August 20, 2024, with the remaining RSUs vesting in equally quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| April 08, 2024 Filed Apr 9, 2024 23:11 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 102,564 | $2.71 | $277,948.44 |
DisclosureSEC source: 0000950170-24-043103 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 531,592 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain performance-based restricted stock units ("RSUs") granted to the reporting person on April 11, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 5, 2024 upon the determination by the Board of Directors of the Issuer that certain of the performance-based conditions were met. Read SEC document |
| April 05, 2024 Filed Apr 5, 2024 22:59 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 212,126 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042373 · ownership.xml · nonDerivative · entry 3 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 634,156 F2 · shares: On April 11, 2023, the Reporting Person was granted a target amount of 231,579 performance-based restricted stock units ("RSUs") under the Issuer's 2011 Equity Incentive Plan, as amended. Each RSU represent the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On April 5, 2024, the Board of Directors of the Issuer determined that certain of the RSU performance-based conditions were met resulting in the vesting of 212,126 RSUs as of March 31, 2024. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 22:59 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 196,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042373 · ownership.xml · derivative · entry 4 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,025 Underlying: Common Stock · 196,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023. F4 · derivative.expiration_date: On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 22:59 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Exercise / conversionCommon Stock | 196,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042373 · ownership.xml · nonDerivative · entry 2 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2024 Filed Apr 5, 2024 22:59 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 9,006 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042373 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,518 F1 · shares: Received in exchange for 8,114 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Issuer"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Issuer's common stock at the effective time of the Merger. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 23:02 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 196,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-23-000019 · wf-form4_168082215819281.xml · derivative · entry 2 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589,537 Underlying: Common Stock · 196,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments beginning April 4, 2023. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments beginning April 4, 2023. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 23:02 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Exercise / conversionCommon Stock | 196,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-23-000019 · wf-form4_168082215819281.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 5,000 shares of Common Stock purchased pursuant to Fluidigm Corporation (currently Standard BioTools Inc.) 2017 Employee Stock Purchase Plan ("ESPP") for the purchase period of June 1, 2022 to November 30, 2022. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 13:44 UTC | IsoPlexis Corp ISO · Entity 115290 | GrantStock Option · Derivative | 89,047 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001062993-22-015242 · form4.xml · derivative · entry 1 Egholm Michael · CIK 0001559779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,047 Underlying: Common Stock · 89,047 shares Expires 2032-06-10 F1 · derivative.exercise_date: Option vests in full on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the next annual shareholders meeting Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 22:35 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 4,529,773 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001162194-22-000045 · wf-form4_164928454559915.xml · derivative · entry 2 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,529,773 Underlying: Common Stock · 4,529,773 shares Expires 2032-04-04 F3 · derivative.exercise_date: The Option becomes exercisable as to 1/4th of the underlying shares on April 4, 2023, and as to an additional 1/48th of the total number of shares each month thereafter. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 22:35 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantRestricted Stock Units · Derivative | 786,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-22-000045 · wf-form4_164928454559915.xml · derivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,049 Underlying: Common Stock · 786,049 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock. F2 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments beginning April 4, 2023. F2 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments beginning April 4, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.